- Orgenesis is a mispriced and misunderstood biotechnology with a pipeline of over 30 licensed gene and cell therapies and a platform called Orgenesis Mobile Processing Labs.
- Due to reinvestment plans and two one-off expenses, the financials looked terrible on a superficial level. This spooked many investors and it created mispricing in the stock.
- Compared to industry peers, we believe Orgenesis should be worth at least $234.8 million. In addition, the company has been buying back shares for the past few months.
For further details see:
Orgenesis: A Mispriced Visionary In Cell And Gene Therapy Manufacturing